Medtronic Tops Charts With InSync FDA Approval Ahead Of Schedule
This article was originally published in The Gray Sheet
Executive Summary
Medtronic will be allowed to use patients enrolled in the trials of its next-generation InSync III to partially fulfill a 1,000-patient, post-approval study requirement for the current generation InSync biventricular pacing system for congestive heart failure, FDA says.
You may also be interested in...
St. Jude Relying On ICD Boom To Weather Slowdown In Pacer Sales
St. Jude continues to benefit from the rapidly expanding ICD market, although pacemaker sales are constrained by competition from cardiac resynchronization therapy (CRT) devices for congestive heart failure
St. Jude Relying On ICD Boom To Weather Slowdown In Pacer Sales
St. Jude continues to benefit from the rapidly expanding ICD market, although pacemaker sales are constrained by competition from cardiac resynchronization therapy (CRT) devices for congestive heart failure
Guidant Stresses Rapid Contak Physician Training To Make Up For Lost Time
Guidant has set a goal of training at least 800 physicians on use of its Contak CD by the end of June. The implantable cardioverter defibrillator was approved May 2 for resynchronization therapy to treat heart failure